Network Pharmacology-based Mechanism of Xiao Xianxiongtang in Treatment of Coronary Heart Disease

Qing-ya GUAN; Jie WANG; Yun ZHANG; Yong-mei LIU; Zhen-peng ZHANG; Xing-jiang XIONG; Jun-ming HE

doi:10.13422/j.cnki.syfjx.20200322

您当前的位置：

首页 >

文章列表页 >

Network Pharmacology-based Mechanism of Xiao Xianxiongtang in Treatment of Coronary Heart Disease

Data Mining | 更新时间：2021-02-09

- Network Pharmacology-based Mechanism of Xiao Xianxiongtang in Treatment of Coronary Heart Disease
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 26, Issue 5, Pages: 152-161(2020)
- 作者机构：
  
  1.湖北中医药大学，武汉　 430065
  2.中国中医科学院　广安门医院，北京　 100053
  3.陕西中医药大学，陕西咸阳　 712083
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.20200322
  CLC： R22; R242; R2-031;R287; R285.5
- Received：12 June 2019，
  
  Published Online：17 October 2019，
  
  Published：05 March 2020
- 稿件说明：
移动端阅览
Qing-ya GUAN, Jie WANG, Yun ZHANG, et al. Network Pharmacology-based Mechanism of Xiao Xianxiongtang in Treatment of Coronary Heart Disease[J]. Chinese journal of experimental traditional medical formulae, 2020, 26(5): 152-161.
DOI：

Qing-ya GUAN, Jie WANG, Yun ZHANG, et al. Network Pharmacology-based Mechanism of Xiao Xianxiongtang in Treatment of Coronary Heart Disease[J]. Chinese journal of experimental traditional medical formulae, 2020, 26(5): 152-161. DOI： 10.13422/j.cnki.syfjx.20200322.

摘要

目的：

通过网络药理学方法预测小陷胸汤治疗冠心病靶标并分析其作用特征，构建“成分-靶标-通路”网络药理模型，揭示小陷胸汤治疗冠心病的潜在通路机制。

方法：

中药系统药理学数据库与分析平台(TCMSP)获得药物有效成分，Swiss靶标预测数据库(Swiss Target Prediction)反向药效团匹配法预测“小陷胸汤-冠心病”靶标；治疗靶标数据库(TTD)，Drugbank，疾病-基因网数据库(DisGeNET)取美国食品和药物管理局(FDA)批准的冠心病并集靶标。韦恩图获得相关交集，GEO2R在线分析靶标特征，Funrich version 3软件分析生物过程，运用插件Reactome FI对靶标通路富集分析，采用Cytoscape软件构建“成分-靶标-通路”网络。

结果：

网络分析表明，小陷胸汤治疗冠心病是通过25个治疗成分调控24个靶标，通过GEO2R在线多个基因芯片分析，靶标存在上下调差异，上调靶标11个，下调靶标13个，作用于4大生物过程，21条具体通路。

结论：

小陷胸汤治疗冠心病的机制可能是通过黄连生物碱类和黄酮类、半夏的核苷类和有机酸类、瓜蒌的豆甾醇类和黄酮类参与基因表达、新陈代谢、蛋白质代谢等生物过程，调节相关靶蛋白的基因表达，调控基因转录通路、生物氧化反应和脂类和脂蛋白代谢、胰岛素样生长因子结合蛋白(IGFBPs)对胰岛素样生长因子(IGF)转运和摄取、细胞外基质的降解等信号通路。

Abstract

Objective:

To predict Xiao Xianxiongtang's treatment of coronary heart disease (CHD) targets and analyze their function by the network pharmacology method

and build ingredients-targets-channel network pharmacological model

in order to reveal potential pathways and mechanisms of Xiao Xianxiongtang for CHD treatment.

Method:

Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) was used to obtain components

and CHD targets over Xiao Xianxiongtang were predicted by using Swiss Target Prediction reverse pharmacophore matching method. CHD targets which Food and Drug Administration (FDA) approved were collected from Therapeutic Target Database (TTD)

Drugbank and Disease-gene Net databases (DisGeNET). Wenn diagram was used to obtain the correlation intersection.Target characteristics were analyzed with GEO2R online

Reactome FI was used to analyze the enrichment of target pathways

and Cytoscape software was used to construct the " component-target-pathway" network.

Result:

Network analysis showed that Xiao Xianxiongtang treated CHD by regulating 24 target proteins through 25 therapeutic components

and acting on 21 specific pathways and 4 biological processes.According to the multiple gene chip analysis of GEO2R online

there were up-down-regulated differences in the targets

including 11 up targets and 13 down targets.

Conclusion:

Xiao Xianxiongtang treats CHD by involving the biological processes through berberine and flavonoid groups of Coptidis Rhizoma

nucleosides and organic acids of

Arum ternatum

Thunb

stigmasterols and flavonoids of

Trichosanthes kirilowii

Maxim

such as gene expression

metabolism and protein metabolism

adjusting the gene expressions of relevant target proteins

regulating gene transcription pathways

such as biological oxidation reaction and lipid and lipoprotein metabolism

insulin-like growth factor binding protein (IGFBPs) of insulin-like growth factor (IGF) transshipment and intake

and the degradation of extracellular matrix signaling pathways.

关键词

Keywords

references

王阶，陈光．冠心病稳定型心绞痛中医诊疗专家共识 [J]．中医杂志， 2018 ， 59 ( 5 ): 447 - 450 .

王慧禹，焦晓民．小陷胸汤合温胆汤治疗冠心病心绞痛60例观察 [J]．中医药临床杂志， 2017 ， 29 ( 2 ): 219 - 221 .

王阶，何庆勇．冠心病心绞痛血瘀证疗效评价标准 [J]．中国实验方剂学杂志， 2018 ， 24 ( 15 ): 1 - 3 .

廖江铨，王阶，刘咏梅，等．高通量测序筛选冠心病血瘀证相关lncRNA-miRNA-mRNA调控网络 [J]．中国实验方剂学杂志， 2017 ， 23 ( 19 ): 28 - 33 .

李圣耀，杨琳，高铸烨，等．清心解瘀方组方中药入血成分的网络药理学分析 [J]．中国实验方剂学杂志， 2018 ， 24 ( 5 ): 198 - 202 .

喻秀兰．加味小陷胸汤对血管内皮细胞保护作用的研究 [D]．武汉：湖北中医学院， 2005 .

刘佳．冠心病血栓前状态相关危险因素分析和Zedoarondiol调控目标miRNA对炎症反应的作用 [D]．北京：中国中医科学院， 2018 .

潘勇．丹参饮合小陷胸汤加味治疗痰瘀痹阻型冠心病稳定型心绞痛的疗效 [J]．中外医疗， 2014 ， 33 ( 18 ): 125 - 126 .

曹现霞．小陷胸汤加减治疗不稳定心绞痛前后脂肪因子visfatin和resistin表达的临床研究 [D]．济南：山东中医药大学， 2010 .

Y LI , J ZHANG , L ZHANG , et al . Systems pharmacology to decipher the combinational anti-migraine effects of Tianshu formula [J]． J Ethnopharmacol ， 2015 ， 174 ( 15 ): 45 - 56 .

H LIU , J WANG , W ZHOU , et al . Systems approaches and polypharmacology for drug discovery from herbal medicines: an example using licorice [J]． J Ethnopharmacol ， 2013 ， 146 ( 3 ): 773 - 793 .

J LI , P ZHAO , Y LI , et al . Systems pharmacology based dissection of mechanisms of Chinese medicinal formula Bufei Yishen as an effective treatment for chronic obstructive pulmonary disease [J]． Sci Rep ， 2015 ， 15 ( 5 ): 1 - 15 .

X LIU , S OUYANG , B YU , et al . PharmMapper server: a web server for potential drug target identification using pharmacophore mapping approach [J]． Nucleic Acids Res ， 2010 ， 141 ( 15 ): 609 - 614 .

Y H LI , C Y YU , X X LI , et al . Therapeutic target database update 2018: enriched resource for facilitating benchto clinic research of targeted therapeutics [J]． Nucleic Acids Res ， 2018 ， 46 ( D1 ): D1121 - D1127 .

S WISHART DAVID , D FEUNANG YANNICK , A C GUO , et al . Drugbank 5.0: a major update to the Drugbank database for 2018 [J]． Nucleic Acids Res ， 2018 ， 46 ( D1 ): D1074 - D1082 .

J PIÑERO , N QUERALT-ROSINACH , À BRAVO ， et al . Disgenet: a discovery platform for the dynamical exploration of human diseases and their genes [J]． Database(Oxford) ， 2015 ， 10 ( 28 ): 1 - 17 .

R SAITO , M E SMOOT , K ONO , et al . A travel guide to Cytoscape plugins [J]． Nat Methods ， 2012 ， 9 ( 11 ): 1069 - 1076 .

L GAO , G ZHAO , J S FANG , et al . Discovery of the neuroprotective effects of alvespimycin by computational prioritization of potential anti-parkinson agents [J]． FEBS J ， 2014 ， 281 ( 4 ): 1110 - 1122 .

姜坤，张明雪．《金匮要略》“阳微阴弦”思想治疗胸痹心痛探析 [J]．辽宁中医杂志， 2019 ， 46 ( 4 ): 691 - 693 .

侯宝松，李星红，刘霞，等．小陷胸汤治疗痰热瘀阻型冠心病心绞痛临床研究 [J]．河南中医， 2018 ， 38 ( 2 ): 201 - 205 .

H YILMAZ-AYDOGAN , O KURNAZ , O KUCUKHUSEYIN , et al . Different effects of PPARA, PPARG and ApoE SNPs on serum lipids in patients with coronary heart disease based on the presence of diabetes [J]． Gene ， 2013 ， 523 ( 1 ): 20 - 26 .

E P HONG , D H KIM , J G SUH , et al . Genetic risk assessment for cardiovascular disease with seven genes associated with plasma C-reactive protein concentrations in Asian populations [J]． Hyper Res , 2014 , 37 ( 7 ): 692 - 698 .

S R MIRHAFEZ , A AVAN , M TAJFARD , et al . Relationship between serum cytokines receptors and matrix metalloproteinase 9 levels and coronary artery disease [J]． J Clin Lab Anal ， 2016 ， 31 ( 5 ): 1 - 4 .

X JI , B K HUANG , G W WANG , et al . The ethnobotanical, phytochemical and pharmacological profile of the genus Pinellia [J]． Fitoterapia ， 2014 ， 93 ( 4 ): 1 - 17 .

H L YU , T F ZHAO , H WU , et al . Pinellia ternata lectin exerts a proinflammatory effect on macrophages by inducing the release of pro-inflammatory cytokines, the activation of the nuclear factor- κ B signalin pathway and the overproduction of reactive oxygen species [J]． Int J Mol Med ， 2015 ， 36 ( 4 ): 1127 - 1135 .

M COFÁN , E ROS ． Clinical application of plant sterol and stanol products [J]． J Aoac Int ， 2015 ， 98 ( 3 ): 701 - 706 .

D A TATA , E K WASAN , K M WASAN , et al . Lipid-lowering activity of natural and semi-synthetic sterols and stanols [J]． J Pharm Pharm Sci ， 2015 ， 18 ( 4 ): 344 - 367 .

T C RIDEOUT , C P F MARINANGELI , S V HARDING ． Triglyceride-lowering response to plant sterol and stanol consumption [J]． J Aoac Int , 2015 , 98 ( 3 ): 707 - 715 .

S Y CHEON , K S CHUNG , K J LEE , et al . HVC1 ameliorates hyperlipidemia and infammation in LDLR-/- mice [J]． BMC Complement Altern Med ， 2017 ， 17 ( 1 ): 1 - 10 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Establishment and Evaluation of Rat Model of Myocardial Ischemia-reperfusion Injury with Phlegm and Blood Stasis Blocking Collaterals Syndrome Based on Metabolomics

Establishment and Evaluation of Rat Model of Acute Myocardial Infarction in Coronary Heart Disease with Qi and Yin Deficiency Syndrome Based on Sleep Deprivation Combined with Coronary Artery Ligation

Mechanism of Xuefu Zhuyutang in Intervening in Ferroptosis in Rats with Coronary Heart Disease with Blood Stasis Syndrome Based on ACSL4 Signalling Pathway

Construction of an Intelligent Diagnosis and Treatment Ontology for Traditional Chinese Medicine Based on Clinical Practice Guidelines：A Case Study of Coronary Heart Disease

Effect of Yiqi Huoxue Prescription on cAMP/Epac1/Rap1 Signaling Pathway in Coronary Heart Disease Rats with Qi Deficiency and Blood Stasis Syndrome

Related Author

HU Longxiao

GAO Jiabei

MA Weihao

LU Jieming

GAO Yunxiao

YUAN Yue

ZHANG Qiuyan

CHEN Xiaoxiao

Related Institution

Natural History Museum of China

Beijing Key Laboratory of Chinese Materia Pharmacology，National Clinical Research Center of Traditional Chinese Medicine for Cardiovascular Diseases，Institute of Basic Medical Sciences， Xiyuan Hospital，China Academy of Chinese Medical Sciences

School of Clinical Medicine，Beijing University of Chinese Medicine

Institute of Basic Medical Sciences，Xiyuan Hospital，China Academy of Chinese Medical Sciences

Provincial Key Laboratory of Traditional Chinese Medicine（TCM） Diagnostics， Hunan University of Chinese Medicine

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰